CAS: 85409-38-7; N-(Dicyclopropylmethyl)-4,5-Dihydrooxazol-2-Amine Phosphate
该化合物是合成甲氨酯的一种药品中间体,一种抗血压剂,有选择地刺激甲状腺素受体,以减少血压.与非磷酸盐相比,该化合物提高了生物利用率和功效,其稳定性和溶性能促进了高效生产过程.
- 英文名称N-(Dicyclopropylmethyl)-4,5-Dihydrooxazol-2-Amine Phosphate
- 中文名称磷酸利美尼定
- IUPAC名称N-(dicyclopropylmethyl)-4,5-dihydrooxazol-2-amine phosphate
- 其它别名Rilmenidine Phosphate; Rilmenidine Dihydrogen Phosphate; Rilmenidine (Phosphate); 2-Oxazolamine, N-(Dicyclopropylmethyl)-4,5-Dihydro-, Phosphate (1:1); 59Qd64Q32M; N-(Dicyclopropylmethyl)-4,5-Dihydro-1,3-Oxazol-2-Amine; Phosphoric Acid; N-(Di
- CAS编号85409-38-7
- MFCD编号:MFCD00875846
- EINECS号:287-106-2
- FDA UNII编号:59QD64Q32M
- 分子式:C10H19N2O5P分子量:278.24
- 产品CID: 1850182
- 产品分类分析化学 → 标准品 → 药典标准品和杂质标准品
物理性质
- 沸点609.1 °C at 760 mmHg
- 闪点322.1 °C
- PSA:121.19
- LogP:0.0487
- 蒸汽压2.11E-16 mmHg at 25 °C
- 溶解性Freely Soluble In Water, Slightly Soluble In Alcohol, Practically Insoluble In Methylene Chloride.
- 外观形态白色至类白色固体
- 储存条件2-8°C
- 产品应用该化合物用作治疗高血压;其抗血压效果与甲状腺素,乙型阻塞剂,钙管阻塞器和血管素-转化酶抑制剂相当;还表明对K562细胞在体外扩散的剂量依赖抑制;在体内,它能改善N171-82Q老鼠的抗血清和抗血脂控制强度,并降低突变人狩猎锡的水平.
MSDS等安全信息
欧盟法规
ECHA物质ECHA物质C&L通报REACH预注册合成工艺路线路线简述
海关参考信息
- 2922110001-单乙醇胺
2909199090-其他醚及其衍生物
2921199090-其他无环单胺 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Perera ND, Sheean RK, Lau CL, Shin YS, Beart PM, Horne MK, Turner BJ. Rilmenidine promotes MTOR-independent autophagy in the mutant SOD1 mouse model of amyotrophic lateral sclerosis without slowing disease progression. Autophagy. 2018;14(3):534-551. doi: 10.1080/15548627.2017.1385674. Epub 2017 Dec 17.
2: Rubinsztein DC, Bento CF, Deretic V. Therapeutic targeting of autophagy in neurodegenerative and infectious diseases. J Exp Med. 2015 Jun 29;212(7):979-90. doi: 10.1084/jem.20150956. Epub 2015 Jun 22. Review.
3: Lim K, Jackson KL, Burke SL, Head GA. The Effects of Rilmenidine and Perindopril on Arousal Blood Pressure during 24 Hour Recordings in SHR. PLoS One. 2016 Dec 21;11(12):e0168425. doi: 10.1371/journal.pone.0168425. eCollection 2016.
合成参考文献
摘要:Cardiovascular Drug Reviews., 8(56), 1990
参考文献:10.1007/s002280050141
摘要:Gentili A, Godschalk MF, Gheorghiu D, Nelson K, Julius DA, Mulligan T. Effect of clonidine and yohimbine on sleep in healthy men: a double-blind, randomized, controlled trial. European Journal of Clinical Pharmacology. 1996 Jul 30;50(6):463–5. doi: 10.1007/s002280050141.
参考文献:10.1007/s10557-006-7653-8
摘要:Teixeira de Castro RR, Tibiriçá E, de Oliveira MAB, Moreira PBB, Catelli MF, Rocha NN, Nóbrega ACL. Reduced Hemodynamic Responses to Physical and Mental Stress Under Low-Dose Rilmenidine in Healthy Subjects. Cardiovascular Drugs and Therapy. 2006 Apr 22;20(2):129–34. doi: 10.1007/s10557-006-7653-8.
参考文献:10.1007/s00210-006-0080-3
摘要:Ernsberger P, Koletsky RJ. Metabolic effects of antihypertensive agents: role of sympathoadrenal and renin-angiotensin systems. Naunyn Schmiedebergs Arch Pharmacol. 2006 Jul;373(4):245–58. doi: 10.1007/s00210-006-0080-3.
参考文献:10.2165/00129784-200101050-00002
摘要:van Zwieten PA. Centrally acting imidazoline I1-receptor agonists: do they have a place in the management of hypertension Am J Cardiovasc Drugs. 2001;1(5):321–6. doi: 10.2165/00129784-200101050-00002.
📝 需求与反馈
尽可能描述清楚需求与问题信息
